Object-oriented influence diagram for cost-effectiveness analysis of influenza vaccination in the Italian elderly population

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 6, Issue 3, 2006, Pages 293-301

  Baio, Gianluca ^a   Pammolli, Fabio ^b   Baldo, Vincenzo ^c   Trivello, Renzo ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b IMT SCHOOL FOR ADVANCED STUDIES LUCCA   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

Influence diagrams; Influenza vaccination; MF59 adjuvanted flu vaccine; Object oriented Bayesian networks

Indexed keywords

INFLUENZA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE;

BAYES THEOREM; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; ERYTHEMA; FEVER; GERIATRIC CARE; HEADACHE; HEALTH PROGRAM; HUMAN; INFLUENZA; INFLUENZA VACCINATION; ITALY; MALAISE; MEDICAL DECISION MAKING; METHODOLOGY; MORBIDITY; MORTALITY; MYALGIA; OUTCOMES RESEARCH; PAIN; PRESCRIPTION; REVIEW;

EID: 33745614590     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.6.3.293     Document Type: Review

References (39)

1. Vu T, Farish S, Jenkins M, Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 20, 1831-1836 (2002).
2. Potter C. A history of influenza. J. Appl. Microbiol. 91, 572-579 (2001).
3. Ansaldi F, Bacilieri S, Banfi F et al. Neutralizing and hemagglutination-inhibiting activities of antibodies elicited by the 2004-2005 influenza vaccine against drifted viruses. Clin. Vaccine Immunol. 13, 162-164 (2006).
4. Nichols K. Cost benefit analysis of a strategy for healthy working adults against influenza. Arch. Intern. Med. 161, 749-759 (2001).
5. Grau A, Fischer B, Barth C et al. Influenza vaccination is associated with a reduced risk of stroke. Stroke 36, 1501-1506 (2005).
6. Nichol K, Nordin J, Mullooly J et al. Influenza vaccination and reduction in hospitalization for cardiac disease and stroke among the elderly. N. Engl. J. Med. 348, 1322-1332 (2003).
7. Nichol K. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 21, 1769-1775 (2003).
8. Armstrong B, Mangtani P, Fletcher A et al. Effect of influenza vaccination on excess deaths during periods of high circulation of influenza: cohort study in elderly people. Br. Med. J. 329, 660 (2004).
9. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 24, 1159-1169 (2006).
10. McElhaney J. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine 23 (Suppl. 1), S10-S25 (2005).
11. Simonsen L, Reichert T, Viboud C et al. Impact of influenza vaccination on seasonal mortality in the us elderly population. Arch. Intern. Med. 165, 265-272 (2005).
12. Jefferson T, Rivetti D, Rudin M, Di Pierantoni C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 366, 1165-1174 (2005).
13. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59C. 1-adjuvanted vaccine. Vaccine 19, 2673-2680 (2001).
14. Banzhoff A, Nacci P, Podda A. A new MF759-adjuvanted influenza vaccine enhances the immune repose in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 49, 177-184 (2003).
15. Puig-Barbera J, Diez-Domingo J, Perez Hoyos S, Belenguer Varea. A, Gonzales Vidal D. Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. Vaccine 23, 283-289 (2004).
16. Iob A, Brianti G, Zamparo E, Gallo T. Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy. Epidemiol. Infect. 133, 687-693 (2005).
17. Baldo V, Menegon T, Bonello C, Floreani A, Trivello R, Collaborative Group. Comparison of three different influenza vaccines in institutionalized elderly. Vaccine 19, 3472-3425 (2001).
18. Menegon T, Baldo V, Bonello C, Dalla Costa D, Di Tommaso A, Trivello R. Influenza vaccines: antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population. Eur. J. Epidemiol. 15, 573-576 (1999).
19. Minutello M, Senatore F, Cecchinelli G et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59C.1 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 17, 99-104 (1999).
20. De Donato S, Granoff D, Minutello M et al. Safety and immunogenicity of MF59C.1-adjuvanted influenza vaccine in the elderly. Vaccine 17, 3094-3101 (1999).
21. Piercy J, Ryan J, Megas F. Economic evaluation of MF59 adjuvanted vaccine against influenza in the high-risk elderly population in France. J. Med. Econ. 7, 1-18 (2004).
22. Pearl J. Probabilistic reasoning in intelligent systems: In: Networks of Plausible Inference. Morgan Kauffman, CA, USA (1988).
23. Eddy D, Hasselblad V, Shachter R. A Bayesian method for synthesizing evidence: the confidence profile method. Int. J. Technol. Assess. Health Care 6, 31-55 (1990).
24. Szolovits P. Uncertainty and decisions in medical informatics. Methods Inf. Med. 34, 111-121 (1995).
25. Owens D, Shachter R, Nease R. Representation and analysis of medical decision problems with influence diagrams. Med. Decis. Making 17, 241-262 (1997).
26. Parmigiani G. Modeling in Medical Decision Making. John Wiley and Sons, NY, USA (2002).
27. Spiegelhalter D, Abrams K, Myles J. Bayesian Approaches To Clinical Trials And Health-Care Evaluation. John Wiley and Sons, Chichester, UK (2004).
28. Spiegelhalter D, Dawid P, Lauritzen S, Cowell R. Bayesian analysis in expert systems. Stat. Sci. 8, 219-283 (1993).
29. Howard R, Matheson J. Readings in Decision Analysis Strategic Decision Group, CA, USA (1981)
30. Shenoy P. A comparison of graphical techniques for decision analysis. Eur. J. Oper. Res. 78, 1-21 (1994)
31. Scuffham P, West P. Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine 20, 2562-2578 (2002).
32. Gasparini R, Lucioni C, Mazzi S, Pregliasco F. Vaccino, adiuvato virosomale vs vaccino tradizionale nella. strategia antinfluenzale: una valutazione farmacoeconomica. Pharmacoeconomics Issues Vaccines Adis International ISBN 88-88371-22-2 (2002).
33. Regione Friuli. Rapporto suila vaccinazione contro l'influenza nella popolazione anziana nella stagione 1997-1998 (1999)
34. Crocetti E, Arniani S, Bordoni F et al. Effectiveness of influenza vaccination in the elderly in a community in Italy. Eur. J. Epidemiol. 17, 163-168 (2001).
35. Gasparini R, Lucioni C, Lai P, De Luca S et al. Influenza surveillance in the Italian region of Liguria in the winter 1999-2000 by general pratictioners and paeditricians: socio-economic implications. J. Prev. Med. Hyg. 42, 83-86 (2001).
36. Montomoli E, Pozzi T, Alfonsi V et al. Valutazione benefici/costi della vaccinazione antinfluenzale in una popolazione di soggetti anziani in due stagioni epidemiche a confronto (1999-2000 - 2000/2001) nella Provincia di Siena. Pharmacoeconomics 5 (Suppl. 1), 31-38 (2002).
37. Jensen F, Dittmer S. From influence diagrams to junction tree. In: Proceedings of the Tenth conference on Uncertainty in Artificial Intelligence. L de Mantras & D Poole (Eds). Morgan Kaufmann Publishers, Edmonton, Canada (1994).
38. Claxton K. The irrelevance of inference: a decision-making approach to stochastic evaluation of health care technologies. J. Health Econ. 18, 342-364 (1999).
39. Claxton K, Schulpher M, McCabe C etal. Probabilistic sensitivity analysis for NICE technology assessments: not an optional extra. Health Econ. 14, 339-347 (2005).